Abbott Receives FDA Approval For Esprit BTK Drug-Eluting Resorbable Scaffold
Executive Summary
The US has greenlighted Abbott’s Esprit BTK System for treating patients with chronic limb-threatening ischemia below the knee, making it the first dissolvable stent to treat this condition. A Wells Fargo analyst sees a $500m US market opportunity for the implant, which will see limited release in late 2024.